| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Image Processing, Computer-Assisted | 34 | 2020 | 232 | 9.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 25 | 2023 | 103 | 5.810 |
Why?
|
| Algorithms | 34 | 2022 | 536 | 4.390 |
Why?
|
| Lymphoma, Follicular | 13 | 2018 | 17 | 3.770 |
Why?
|
| Pattern Recognition, Automated | 14 | 2015 | 36 | 3.590 |
Why?
|
| Diagnosis, Computer-Assisted | 11 | 2019 | 52 | 3.370 |
Why?
|
| Microscopy | 9 | 2019 | 28 | 2.830 |
Why?
|
| Ki-67 Antigen | 5 | 2023 | 32 | 2.280 |
Why?
|
| Artificial Intelligence | 11 | 2023 | 63 | 2.100 |
Why?
|
| Breast Neoplasms | 9 | 2023 | 762 | 1.570 |
Why?
|
| Cell Nucleus | 4 | 2018 | 111 | 1.540 |
Why?
|
| User-Computer Interface | 8 | 2017 | 54 | 1.470 |
Why?
|
| Immunohistochemistry | 7 | 2019 | 545 | 1.460 |
Why?
|
| Reproducibility of Results | 20 | 2020 | 757 | 1.450 |
Why?
|
| Humans | 76 | 2024 | 32282 | 1.440 |
Why?
|
| Neuroblastoma | 7 | 2017 | 32 | 1.350 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 219 | 1.220 |
Why?
|
| Pathology | 3 | 2019 | 20 | 1.190 |
Why?
|
| Information Storage and Retrieval | 6 | 2020 | 26 | 1.080 |
Why?
|
| Prognosis | 10 | 2024 | 1534 | 1.080 |
Why?
|
| Software | 7 | 2017 | 124 | 1.050 |
Why?
|
| Neuroendocrine Tumors | 2 | 2018 | 19 | 0.970 |
Why?
|
| Histocytochemistry | 4 | 2016 | 34 | 0.970 |
Why?
|
| Tympanic Membrane | 3 | 2020 | 4 | 0.940 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 1224 | 0.900 |
Why?
|
| Brain Neoplasms | 4 | 2017 | 637 | 0.890 |
Why?
|
| Staining and Labeling | 5 | 2020 | 63 | 0.860 |
Why?
|
| Diagnostic Imaging | 4 | 2017 | 89 | 0.850 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 461 | 0.820 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 19 | 0.810 |
Why?
|
| Neoplasms | 3 | 2023 | 754 | 0.800 |
Why?
|
| Lung | 3 | 2015 | 263 | 0.710 |
Why?
|
| Sensitivity and Specificity | 13 | 2018 | 556 | 0.710 |
Why?
|
| Pathology, Clinical | 3 | 2017 | 11 | 0.690 |
Why?
|
| Phantoms, Imaging | 2 | 2018 | 70 | 0.680 |
Why?
|
| Osteoarthritis, Knee | 2 | 2012 | 69 | 0.670 |
Why?
|
| Cystic Fibrosis | 2 | 2013 | 25 | 0.660 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 2 | 2017 | 2 | 0.640 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2017 | 3 | 0.640 |
Why?
|
| Pathology, Surgical | 1 | 2019 | 2 | 0.630 |
Why?
|
| Biopsy | 3 | 2018 | 252 | 0.580 |
Why?
|
| Rosacea | 1 | 2019 | 46 | 0.580 |
Why?
|
| Female | 25 | 2023 | 19945 | 0.570 |
Why?
|
| Osteoarthritis | 2 | 2010 | 73 | 0.570 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2013 | 38 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2022 | 907 | 0.560 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 39 | 0.550 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 140 | 0.550 |
Why?
|
| Skin Diseases | 1 | 2019 | 135 | 0.540 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 189 | 0.540 |
Why?
|
| Image Enhancement | 8 | 2014 | 66 | 0.530 |
Why?
|
| Observer Variation | 5 | 2020 | 96 | 0.520 |
Why?
|
| Gliosis | 1 | 2017 | 5 | 0.510 |
Why?
|
| Histology | 3 | 2016 | 5 | 0.500 |
Why?
|
| Antibodies | 1 | 2017 | 56 | 0.500 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2011 | 132 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 131 | 0.500 |
Why?
|
| Liver | 2 | 2016 | 492 | 0.490 |
Why?
|
| Abdomen | 1 | 2016 | 44 | 0.480 |
Why?
|
| Radiology Information Systems | 4 | 2007 | 12 | 0.470 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 79 | 0.460 |
Why?
|
| Fatty Liver | 1 | 2016 | 70 | 0.460 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2015 | 6 | 0.440 |
Why?
|
| Lymphoma | 2 | 2018 | 37 | 0.420 |
Why?
|
| Brain | 3 | 2022 | 965 | 0.420 |
Why?
|
| Child | 6 | 2023 | 2435 | 0.410 |
Why?
|
| Granuloma | 1 | 2013 | 14 | 0.410 |
Why?
|
| Glioblastoma | 1 | 2015 | 159 | 0.410 |
Why?
|
| Stromal Cells | 3 | 2009 | 66 | 0.400 |
Why?
|
| Lymphocytes | 1 | 2013 | 56 | 0.400 |
Why?
|
| Knowledge Bases | 1 | 2012 | 4 | 0.370 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 242 | 0.370 |
Why?
|
| Data Mining | 1 | 2012 | 14 | 0.370 |
Why?
|
| Femur | 2 | 2011 | 75 | 0.360 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 489 | 0.340 |
Why?
|
| Male | 13 | 2020 | 19441 | 0.340 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2011 | 17 | 0.340 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2011 | 26 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 31 | 0.330 |
Why?
|
| Tibia | 1 | 2011 | 56 | 0.330 |
Why?
|
| Quadriceps Muscle | 1 | 2010 | 29 | 0.310 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 93 | 0.300 |
Why?
|
| Otoscopy | 2 | 2020 | 2 | 0.300 |
Why?
|
| Ear Diseases | 2 | 2020 | 7 | 0.300 |
Why?
|
| Histological Techniques | 1 | 2009 | 8 | 0.290 |
Why?
|
| Cytological Techniques | 1 | 2009 | 17 | 0.290 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 20 | 0.290 |
Why?
|
| Osteoarthritis, Hip | 1 | 2009 | 17 | 0.290 |
Why?
|
| Tumor Burden | 1 | 2009 | 63 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 43 | 0.280 |
Why?
|
| Systems Integration | 1 | 2007 | 11 | 0.270 |
Why?
|
| Adult | 10 | 2023 | 9259 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 37 | 0.270 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 49 | 0.260 |
Why?
|
| Meningioma | 1 | 2008 | 59 | 0.260 |
Why?
|
| Cluster Analysis | 3 | 2014 | 120 | 0.260 |
Why?
|
| ROC Curve | 3 | 2018 | 169 | 0.260 |
Why?
|
| Medical Informatics | 2 | 2018 | 26 | 0.240 |
Why?
|
| Databases as Topic | 3 | 2020 | 20 | 0.240 |
Why?
|
| Adipose Tissue | 1 | 2009 | 320 | 0.240 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 130 | 0.240 |
Why?
|
| Radiographic Image Enhancement | 2 | 2002 | 30 | 0.230 |
Why?
|
| Glioma | 2 | 2017 | 137 | 0.230 |
Why?
|
| Medical Oncology | 1 | 2006 | 90 | 0.220 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 520 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 33 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2024 | 29 | 0.210 |
Why?
|
| Habits | 1 | 2023 | 2 | 0.200 |
Why?
|
| Otolaryngology | 2 | 2020 | 16 | 0.190 |
Why?
|
| Metal Nanoparticles | 1 | 2023 | 16 | 0.190 |
Why?
|
| Otitis Media | 1 | 2023 | 24 | 0.190 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2002 | 6 | 0.190 |
Why?
|
| Tomography, Spiral Computed | 1 | 2002 | 19 | 0.190 |
Why?
|
| Nanoparticles | 1 | 2023 | 52 | 0.190 |
Why?
|
| Breast | 1 | 2023 | 63 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 883 | 0.180 |
Why?
|
| Computers | 2 | 2015 | 22 | 0.180 |
Why?
|
| Risk | 1 | 2023 | 305 | 0.180 |
Why?
|
| Health Personnel | 1 | 2023 | 112 | 0.180 |
Why?
|
| Area Under Curve | 2 | 2018 | 90 | 0.180 |
Why?
|
| Internet | 2 | 2017 | 202 | 0.180 |
Why?
|
| Discriminant Analysis | 3 | 2011 | 20 | 0.180 |
Why?
|
| Color | 3 | 2011 | 12 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2017 | 553 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2018 | 368 | 0.170 |
Why?
|
| Telemedicine | 2 | 2020 | 122 | 0.170 |
Why?
|
| Middle Aged | 7 | 2018 | 11851 | 0.170 |
Why?
|
| Calcinosis | 1 | 2002 | 143 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2015 | 187 | 0.170 |
Why?
|
| Fourier Analysis | 2 | 2011 | 7 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 595 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2018 | 603 | 0.160 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 255 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 443 | 0.160 |
Why?
|
| Mice | 6 | 2017 | 2571 | 0.160 |
Why?
|
| Face | 1 | 2019 | 29 | 0.150 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 168 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 74 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 20 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2019 | 113 | 0.150 |
Why?
|
| Gene Expression | 2 | 2017 | 346 | 0.150 |
Why?
|
| Data Compression | 1 | 2018 | 1 | 0.140 |
Why?
|
| Software Design | 2 | 2009 | 6 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 34 | 0.140 |
Why?
|
| Aged | 5 | 2017 | 10263 | 0.140 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2009 | 47 | 0.140 |
Why?
|
| Molecular Imaging | 1 | 2018 | 18 | 0.140 |
Why?
|
| Computer Communication Networks | 2 | 2007 | 4 | 0.130 |
Why?
|
| Database Management Systems | 2 | 2007 | 11 | 0.130 |
Why?
|
| Isoindoles | 1 | 2017 | 6 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 7 | 0.130 |
Why?
|
| Automation | 2 | 2009 | 28 | 0.130 |
Why?
|
| Dacarbazine | 1 | 2017 | 31 | 0.130 |
Why?
|
| Benzamides | 1 | 2017 | 60 | 0.130 |
Why?
|
| Entropy | 1 | 2017 | 11 | 0.130 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 2 | 0.130 |
Why?
|
| Animals | 8 | 2017 | 8199 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 93 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2018 | 393 | 0.120 |
Why?
|
| Proteomics | 1 | 2017 | 97 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 504 | 0.120 |
Why?
|
| Prostate | 1 | 2016 | 88 | 0.110 |
Why?
|
| Tuberculosis | 1 | 2015 | 17 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 81 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2020 | 308 | 0.110 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 15 | 0.110 |
Why?
|
| Probability | 1 | 2015 | 155 | 0.110 |
Why?
|
| Neutrophils | 1 | 2015 | 120 | 0.110 |
Why?
|
| Photography | 1 | 2015 | 42 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2015 | 139 | 0.110 |
Why?
|
| Hematoxylin | 1 | 2013 | 4 | 0.100 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cell Count | 1 | 2013 | 51 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 24 | 0.100 |
Why?
|
| Adolescent | 3 | 2017 | 3519 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2013 | 99 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2017 | 1233 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 93 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2013 | 91 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 729 | 0.090 |
Why?
|
| Flavonoids | 1 | 2012 | 20 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2013 | 91 | 0.090 |
Why?
|
| Natural Language Processing | 1 | 2012 | 7 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 116 | 0.090 |
Why?
|
| Autophagy | 1 | 2012 | 55 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 106 | 0.090 |
Why?
|
| Piperidines | 1 | 2012 | 137 | 0.090 |
Why?
|
| Apoptosis | 1 | 2013 | 375 | 0.080 |
Why?
|
| Cell Shape | 1 | 2011 | 28 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2011 | 37 | 0.080 |
Why?
|
| Cell Size | 1 | 2011 | 40 | 0.080 |
Why?
|
| Cells | 1 | 2010 | 5 | 0.080 |
Why?
|
| Lymphoma, T-Cell | 1 | 2010 | 4 | 0.080 |
Why?
|
| Infant | 1 | 2013 | 1010 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 9 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 26 | 0.080 |
Why?
|
| Europe | 1 | 2009 | 82 | 0.080 |
Why?
|
| Pattern Recognition, Physiological | 1 | 2009 | 4 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2009 | 32 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2009 | 119 | 0.070 |
Why?
|
| Mitosis | 1 | 2009 | 17 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 14 | 0.070 |
Why?
|
| Respiratory System | 1 | 2009 | 11 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2009 | 29 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2009 | 50 | 0.070 |
Why?
|
| Thigh | 1 | 2009 | 35 | 0.070 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 28 | 0.070 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 67 | 0.070 |
Why?
|
| Cell Death | 1 | 2009 | 79 | 0.070 |
Why?
|
| Radiography | 1 | 2010 | 363 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 3900 | 0.070 |
Why?
|
| Contrast Media | 1 | 2009 | 136 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2013 | 3416 | 0.070 |
Why?
|
| Data Display | 1 | 2007 | 2 | 0.070 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2007 | 3 | 0.070 |
Why?
|
| Computer Security | 1 | 2007 | 8 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3626 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 651 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2007 | 40 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2009 | 178 | 0.060 |
Why?
|
| Computational Biology | 1 | 2007 | 99 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2017 | 727 | 0.060 |
Why?
|
| Inflammation | 1 | 2009 | 506 | 0.060 |
Why?
|
| Equipment Design | 1 | 2006 | 178 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2015 | 59 | 0.050 |
Why?
|
| United States | 2 | 2009 | 4072 | 0.050 |
Why?
|
| Static Electricity | 1 | 2023 | 13 | 0.050 |
Why?
|
| Nanotechnology | 1 | 2023 | 18 | 0.050 |
Why?
|
| Gold | 1 | 2023 | 19 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2002 | 27 | 0.050 |
Why?
|
| Echoencephalography | 1 | 2022 | 4 | 0.050 |
Why?
|
| Quality Control | 1 | 2002 | 43 | 0.050 |
Why?
|
| Temporal Bone | 1 | 2022 | 19 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 1083 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 245 | 0.050 |
Why?
|
| Mammography | 1 | 2002 | 41 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 223 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 743 | 0.040 |
Why?
|
| Video Recording | 1 | 2020 | 61 | 0.040 |
Why?
|
| China | 1 | 2018 | 56 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 423 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 521 | 0.030 |
Why?
|
| World Health Organization | 1 | 2018 | 17 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Acoustic Impedance Tests | 1 | 2017 | 4 | 0.030 |
Why?
|
| Ear Canal | 1 | 2017 | 4 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 66 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 23 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 33 | 0.030 |
Why?
|
| Otitis Media with Effusion | 1 | 2017 | 12 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 80 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2017 | 52 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 114 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 74 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 78 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 96 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 167 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 292 | 0.030 |
Why?
|
| Chemokine CXCL5 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Chemokine CXCL2 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1241 | 0.030 |
Why?
|
| Chemokines | 1 | 2015 | 34 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 54 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 893 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 591 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1840 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 215 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 381 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 237 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 3 | 0.020 |
Why?
|
| Diffusion | 1 | 2013 | 17 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 1425 | 0.020 |
Why?
|
| Cell Communication | 1 | 2013 | 37 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 792 | 0.020 |
Why?
|
| Starvation | 1 | 2012 | 2 | 0.020 |
Why?
|
| Vidarabine | 1 | 2012 | 6 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 7 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 24 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 288 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 19 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 164 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 821 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 90 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 170 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 408 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 6 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 20 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 23 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 91 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 2649 | 0.020 |
Why?
|
| Drug Design | 1 | 2010 | 51 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 48 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2010 | 53 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 27 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 66 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 60 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2009 | 82 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 257 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 258 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 256 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2007 | 10 | 0.020 |
Why?
|
| Radiology | 1 | 2007 | 34 | 0.020 |
Why?
|